Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Xueying Li, He Huang, Bing Xu, Hongqiang Guo, Yingcheng Lin, Sheng Ye, Jiqun Yi, Wenyu Li, Xiangyuan Wu, Wei Wang, Hongyu Zhan, Derong Xie, Jiewen Peng, Yabing Cao, Xingxiang Pu, Chengcheng Guo, Huangming Hong, Zhao Wang, Xiaojie Fang, Yong Zhou, Suxia Lin, Qing Liu, Tongyu Lin
Cancer Res Treat. 2019;51(3):919-932.   Published online 2018 Oct 2     DOI: https://doi.org/10.4143/crt.2018.230
Citations to this article as recorded by Crossref logo
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
Murali Kesavan, Toby A. Eyre, Graham P. Collins
Current Hematologic Malignancy Reports.2019;[Epub]     CrossRef